Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05297578 · ClinicalTrials.gov registry record · Phase 2

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults

A Phase 2 study of Pneumococcal Vaccines, sponsored by Vaxcyte.

Completed
Registry status
Phase 2
Development phase
207
Enrollment target
20
Study locations

NCT05297578: Completed Phase 2 study of Pneumococcal Vaccines, sponsored by Vaxcyte.

NCT05297578 is a Phase 2 study of Pneumococcal Vaccines that has completed, run by Vaxcyte. The registered enrollment target is 207 participants, below the 1,545-participant average among 5 other Pneumococcal Vaccines trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05297578, a Phase 2 study of Pneumococcal Vaccines, has completed, sponsored by Vaxcyte.

COMPLETED
Registry status
Phase 2
Development phase
207 participants
Enrollment target
20
Study locations

Study Summary

The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 65 years of age and older.

Primary Outcome

Solicited local reactions included redness/erythema, swelling/induration, and pain at injection site

Conditions Studied

Interventions

  • BIOLOGICAL Pneumococcal 20-valent Conjugate Vaccine
  • BIOLOGICAL 24-Valent Pneumococcal Conjugate Vaccine

Study Locations (20)

Florida

  • Accel Research Sites - DeLand Clinical Research Unit - DeLand
  • CenExel RCA - Hollywood
  • Precision Clinical Research - Sunrise

Georgia

  • Meridian Clinical Research - Savannah
  • Pivotal Research Solutions - Stonecrest

Kansas

  • AMR Newton, formerly Heartland Research Associates - Newton
  • AMR Wichita West - Wichita

South Carolina

  • Accellacare of Charleston - Mt. Pleasant
  • Coastal Carolina Research - North Charleston

Utah

  • CenExel JBR Clinical Research - Salt Lake City
  • Velocity Clinical Research, Salt Lake City - West Jordan

Alabama

  • Accel Research Sites-Birmingham Clinical Research Unit - Birmingham

Illinois

  • Healthcare Research Network II, LLC - Flossmoor

Louisiana

  • AMR New Orleans - New Orleans

Trial Details

FieldValue
Enrollment Target 207 participants
Start Date 2022-06-15
Est. Completion 2023-02-15
Phase Phase 2
Vaxcyte

8 total trials

What the finished NCT05297578 record still lists

NCT05297578 is an interventional study that assigns participants to a tested intervention. The registered 207 participants enrollment target is mid-sized for trials with a published cap, below the 1,545-participant average among 5 other Pneumococcal Vaccines trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Pneumococcal Vaccines appearing as the primary indexed condition, and to 2 interventions - of which Pneumococcal 20-valent Conjugate Vaccine is the first listed.

NCT05297578 names 20 study sites across 14 states, led by Florida, Georgia, Kansas.

Frequently Asked Questions

What is clinical trial NCT05297578 about?

NCT05297578 is a clinical study titled "Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults". The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 65 years of age and older.

What is the current status of trial NCT05297578?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 207 participants. The study started on 2022-06-15. Estimated completion is 2023-02-15.

What conditions does trial NCT05297578 study?

This clinical trial studies the following conditions: Pneumococcal Vaccines.

What interventions are being tested in trial NCT05297578?

The interventions under investigation include: Pneumococcal 20-valent Conjugate Vaccine (BIOLOGICAL), 24-Valent Pneumococcal Conjugate Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT05297578?

This trial is sponsored by Vaxcyte, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05297578 being conducted?

This trial has 20 study locations across Alabama, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pneumococcal Vaccines

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04353778 · 207 participants · Phase 1

    Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV

  • NCT05875805 · 207 participants · NA

    A Telehealth Advance Care Planning Intervention

  • NCT06254950 · 207 participants · Phase 2

    A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

  • NCT06904274 · 207 participants · Phase 3

    Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05297578, the US trial registry maintained by the National Library of Medicine. NCT05297578 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.